SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as part of a broader surge in quantum computing stocks, with community members debating whether the company's valuation is justified amidst significant price appreciation and comparisons to other high-growth sectors. Discussions also revolve around potential short squeezes and the long-term viability of quantum computing investments.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending due to a new partnership with Perplexity AI, aiming to enhance content discovery and offer a bundled subscription service. The community is buzzing about the potential impact on Rumble's platform and revenue streams, with some speculating about a possible short squeeze given the high short interest and Trump's backing.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum (QBTS) is trending amid general excitement in the quantum computing sector, with community members highlighting its potential for energy-efficient solutions. Some traders are discussing potential breakouts and short squeezes, while others compare QBTS to other quantum and AI stocks. Recent news and government initiatives in quantum tech appear to be driving interest.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as users highlight its association with weed culture and its potential for growth, drawing comparisons to Bitcoin. Community members emphasize Weedcoin's focus on freedom, natural growth, and cultural connection, promoting it as more than just a cryptocurrency. Discussions also involve community links and contract addresses.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending as the quantum computing sector gains momentum, with community members actively discussing its potential and comparing it to other players like $QBTS and $RGTI. Bullish sentiment is fueled by the company's collaborations, and some traders anticipate a short squeeze as the stock approaches all-time highs. Others remain skeptical, pointing to valuation concerns and the long-term horizon for quantum computing commercialization.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as investors watch for a breakout above the stubborn $40 resistance level, fueled by optimism surrounding expansion and potential market dominance. Community members are actively discussing the possibility of a short squeeze and the potential for a Nasdaq relisting, which they believe would unlock further gains. The stock's movement is also being compared to that of other Chinese equities and coffee competitors.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as investors react to news of a partnership with Corning, anticipating a boost in next-generation battery production and a move closer to commercialization. The community is highly bullish, discussing potential price targets and new partnerships, while also expressing excitement over the company's long-term potential in the solid-state battery sector. Some traders believe this move validates QuantumScape's technology and scaling capabilities, leaving skeptics and short sellers behind.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as it approaches its all-time high, driven by optimism around potential Federal Reserve interest rate cuts and a generally bullish sentiment in the crypto market. Community members are actively discussing potential new ATHs, longing for a sustained breakout, and speculating about market manipulation. Some are also drawing comparisons to past bull runs and altcoin season.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is trending as community members discuss the potential impact of recent news, including a private placement, on the stock. Some are optimistic about the company's future and potential government backing, while others express concerns about revenue and valuation, leading to a debate on the stock's prospects. Trading volume and options activity are elevated compared to average levels.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Alto Neuroscience (ANRO) is trending due to its FDA Fast Track designation for ALTO-101, a potential treatment for cognitive impairment associated with schizophrenia, which has no currently approved treatments. The community is actively discussing the stock's potential for significant gains if Phase 2 data is positive, given the unmet medical need and substantial market size. Discussions also include institutional ownership, cash runway, and potential short squeezes.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KalVista Pharmaceuticals (KALV) announced on Friday that the European Commission (EC) and the Swiss Agency for Therapeutic Products, Swissmedic, have approved its Ekterly for the symptomatic treatment of acute attacks of hereditary angioedema (HAE).Ekterly was approved by both agencies for the treatment of adults and adolescents aged 12 years and older with HAE. It is the first and only oral on-demand treatment for HAE in the two regions, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-announces-european-commission-and">said</a>.Shares of the company traded lower by 2% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KALV">KalVista</a> stayed within ‘bullish’ territory over the past 24 hours, while message volume stayed within ‘normal’ levels.<figure class="image"><img style="aspect-ratio:573/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_19_at_12_33_07_PM_png_055493ce17.webp" alt="KALV's Sentiment Meter and Message Volume as of 12:33 p.m. ET on Sept. 19, 2025 | Source: Stocktwits" width="573" height="62"><figcaption>KALV's Sentiment Meter and Message Volume as of 12:33 p.m. ET on Sept. 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user sees the stock rallying to $22 in 12 months.<stembedurl>https://stocktwits.com/PokerMunkee/message/629305223</stembedurl>Another opined that the stock has a lot of “potential and great setup.”<stembedurl>https://stocktwits.com/Shakattack31/message/629258146</stembedurl>“With our U.S. launch progressing well and approvals now secured in the U.K., EU, and Switzerland, we look forward to bringing this innovation to more people living with HAE, beginning with our first European launch in Germany,” CEO Ben Palleiko said. The company expects to launch Ekterly in Germany in the fourth quarter and in Switzerland in the second half of 2026.The recent approvals are based on the results of a late-stage trial where Ekterly achieved significantly faster symptom relief, reduction in attack severity, and attack resolution than placebo. The results also showed that the drug was well-tolerated, with a safety profile similar to that of the placebo.The EC approval applies to all 27 EU member states as well as Iceland, Liechtenstein, and Norway. In August, the European Medicines Agency also granted Ekterly 10 years of market exclusivity.Hereditary angioedema (HAE) is a rare genetic disease caused by a deficiency or dysfunction of a protein called the C1 esterase inhibitor, where patients experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected. Ekterly <a href="https://stocktwits.com/news-articles/markets/equity/kalvista-gets-fda-approval-for-drug-in-treating-swelling-disorder/chFtmFCR57B">received</a> approval from the U.S. Food and Drug Administration for the treatment of HAE in July.KALV stock is up by about 61% this year and by about 24% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/emergent-biosolutions-stock-rises-after-receiving-fresh-international-purchase-orders/chD3729R3Tf">Emergent BioSolutions Stock Rises After Receiving Fresh International Purchase Orders: Retail Says Stock Is ‘Significantly Undervalued’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

KalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A Year

Ekterly is now the first and only oral on-demand treatment for hereditary angioedema in the two regions, the company said. 

Equity

Ekterly is now the first and only oral on-demand treatment for hereditary angioedema in the two regions, the company said. 


KalVista Pharmaceuticals, Inc. (KALV) Reports Q1 Loss, Lags Revenue Estimates

KalVista Pharmaceuticals (KALV) delivered earnings and revenue surprises of -23.08% and -20.91%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?

KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?

KalVista jumps 36% in a week after the FDA clears Ekterly, the first oral on-demand therapy for hereditary angioedema.

KalVista Pharmaceuticals, Inc. (KALV) on Monday said that the U.S. Food and Drug Administration (FDA) has approved its drug Ekterly for the treatment of acute attacks of hereditary angioedema in adults and children aged 12 years and older.<a href="https://stocktwits.com/symbol/KALV">KalVista</a>’s shares were up over 17% in pre-market trading.Hereditary angioedema (HAE) is a rare genetic disease caused by deficiency or dysfunction of a protein called the C1 esterase inhibitor, where patients experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected.Ekterly is the first and only oral on-demand treatment for HAE, KalVista <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-announces-fda-approval-ekterlyr">said</a>, setting it apart from other on-demand HAE treatment options approved in the U.S., which require intravenous or subcutaneous administration.Even with the use of long-term prophylaxis as a preventative therapy, most people living with HAE continue to have unpredictable attacks and require on-demand access to medication, the company added.KalVista will launch Ekterly in the U.S. immediately, and physicians can begin writing prescriptions on Monday.The approval was based on results from a late-stage study in 136 patients, showing that Ekterly achieved significantly faster symptom relief, a reduction in attack severity, and an increase in attack resolution compared to the placebo. The results also showed that the drug was well-tolerated, with a safety profile similar to that of the placebo.A later study also showed that Ekterly enabled patients to treat attacks in a median of 10 minutes following onset.On Stocktwits, retail sentiment around KalVista jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_07_at_8_56_04_AM_png_8e1123c17a.webp" alt="KALV's Sentiment Meter and Message Volume as of 8:55 a.m. ET on July 7, 2025 | Source: Stocktwits" width="626" height="67"><figcaption>KALV's Sentiment Meter and Message Volume as of 8:55 a.m. ET on July 7, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism for the stock hitting as high as $50 upon the news.<stembedurl>https://stocktwits.com/fzriderz/message/620039415</stembedurl>KALV stock is up by over 41% this year and down by about 2% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/shell-signals-earnings-dip-in-trading-in-q2-but-refining-margin-to-improve/chFthjLR5PR">Shell Signals Earnings Dip In Trading In Q2, But Refining Margin To Improve</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

KalVista Stock Soars Pre-Market On FDA Approval For Drug In Treating Swelling Disorder: Retail’s Elated

Ekterly is the first and only oral on-demand treatment for hereditary angioedema, KalVista said, setting it apart from other on-demand treatment options approved in the U.S., which require intravenous or subcutaneous administration. 

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following investor conferences: TD Cowen 45th Annual Health Care...

KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that six abstracts have been accepted for presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy...

KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the presentation of novel data related to long-term prophylaxis and sebetralstat at the Western Society of Allergy, Asthma & Immunology...

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVistas board of directors granted fifty-two newly-hired employees inducement options to purchase...

KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japans Ministry of Health, Labour and Welfare (MHLW) has granted sebetralstat Orphan Drug Designation. The Company has also...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that the compensation committee of KalVistas board of directors granted nine newly-hired employees inducement options to purchase an...

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.

KalVista Pharmaceuticals Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$11.85
Prev Close	$11.75
Open	$11.81
Dividend Yield	0.00%
50-Day Moving Average	$13.44
Beta	0.34
Avg. Volume	1.44M
PE Ratio	-2.94

52-Week High	$17.28
52-Week Low	$7.30
Market Capitalization	$593.65M
EPS (Annual)	-$3.69
Price to Book	14.50
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

KALV
KalVista Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KALV News

KALV KalVista Pharmaceuticals Inc